SavedAdd your journal

Journals / Eastern Journal of Medicine / 2022 / Cilt: 27 - Sayı: 2

The Effects of Rutaecarpine on Metastatic Prostate Cancer Cells

Mehmet Abuldukadir ŞEKEROĞLU
Erdem ÇOKLUK
Mehmet Ramazan ŞEKEROĞLU
Fatma Betül TUNCER
Zeynep ÖZMAN
Gamze Güney ESKİLER
Pages
302–306
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

RUT induced cytotoxicity and apoptotic cell death were evaluated by WST-1, Annexin V, AO staining and ELISA assays in PC-3 human metastatic prostate cancer cell line.The viability percentage of PC-3 cells after exposing to different concentrations of RUT treatment significantly decreased in a time and dose dependent manner and the most effective concentrations of RUT was determined as 20 and 40 μM for 48 hours (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Prostate cancer with an increased incidence in the world is one of the public health-threatening malignancy.
📊
Key Findings & Data:Therefore, there is a need to de velop novel treatment strategies in metastatic prostate cancer patients.
💡
Conclusion & Impact:RUT induced cytotoxicity and apoptotic cell death were evaluated by WST-1, Annexin V, AO staining and ELISA assays in PC-3 human metastatic prostate cancer cell line.The viability percentage of PC-3 cells after exposing to different concentrations of RUT treatment significantly decreased in a time and dose dependent manner and the most effective concentrations of RUT was determined as 20 and 40 μM for 48 hours (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Prostate cancer with an increased incidence in the world is one of the public health-threatening malignancy. Metastatic prostate cancer is an important cause of death in men despite of the combined use of more than one chemotherapeutic drug as well as radiotherapy and supportive treatments. Therefore, there is a need to de velop novel treatment strategies in metastatic prostate cancer patients. The aim of this study was to investigate the potential therapeutic effects of Rutaecarpine (RUT) on metastatic prostate cancer cells. RUT induced cytotoxicity and apoptotic cell death were evaluated by WST-1, Annexin V, AO staining and ELISA assays in PC-3 human metastatic prostate cancer cell line.The viability percentage of PC-3 cells after exposing to different concentrations of RUT treatment significantly decreased in a time and dose dependent manner and the most effective concentrations of RUT was determined as 20 and 40 μM for 48 hours (p

🔖

Cite This Article

ŞEKEROĞLU, M. A., ÇOKLUK, E., ŞEKEROĞLU, M. R., TUNCER, F. B., ÖZMAN, Z., ESKİLER, G. G. (2022). The Effects of Rutaecarpine on Metastatic Prostate Cancer Cells. Eastern Journal of Medicine, Cilt: 27 - Sayı: 2, 302–306. https://ajindex.com/articles/494654

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer 2018; 378: 1408-1418.
  2. Perdana NR, Mochtar CA, Umbas R, Hamid AJAMI. The risk factors of prostate cancer and its prevention: a literature review 2016; 48: 228-238.
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7- 34. Akdemir en. Prostat kanserli hastalarda primer evrelemede ve nüks hastaliğin saptanmasinda 68ga-psma pet-bt’nin yeri. 2017. ASA SJTKNT-ÖK. Prostat Kanserinde Metastazların Saptanmasında PET/BT ile PET/MR'ın Kıyaslanması 2019; 5: 20-23.
  4. Önerileri KY, Başaran M, Bavbek S, Çal Ç, İğdem Ş, Özen H, et al. Prostat Kanseri Yol Haritası: Uluslararası Kılavuzlar ve Klinik Deneyimler Işığında Prostat. 7. James N, Mason MJJCO. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: first survival results from STAMPEDE 2015; 33: 5001. Lee SH, Son J-K, Jeong BS, Jeong T-C, Chang HW, Lee E-S, et al. Progress in the studies on rutaecarpine 2008; 13: 272-300.
  5. Jiang J, Hu CJM. Evodiamine: a novel anti cancer alkaloid from Evodia rutaecarpa 2009; 14: 1852-1859.
  6. Liu Y-N, Pan S-L, Liao C-H, Huang D-Y, Guh J-H, Peng C-Y, et al. Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1α accumulation in RAW264. 7. 2009; 32: 263-269. Pešek T. Design and synthesis of rutaecarpine analogs as potential cytotoxic agents for cancer chemotherapy treatment. 2015.
  7. Wang T, Wang Y, Kontani Y, Kobayashi Y, Sato Y, Mori N, et al. Evodiamine improves diet-induced obesity in a uncoupling protein 1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling 2008; 149: 358-366.
  8. Yan L, Li QF, Rong YT, Chen YH, Huang ZH, Wang ZZ, et al. The protective effects of rutaecarpine on acute pancreatitis 2018; 15: 3121-3126.
  9. Collignon J, Lousberg L, Schroeder H, Jerusalem GJBCT, Therapy. Triple-negative breast cancer: treatment challenges and solutions 2016; 8: 93. Kan SF, Huang WJ, Lin LC, Wang PSJIjoc. Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP 2004; 110: 641-651.
  10. Guo H, Liu D, Gao B, Zhang X, You M, Ren H, et al. Antiproliferative activity and cellular uptake of evodiamine and rutaecarpine based on 3D tumor models 2016; 21: 954. Xu M-L, Moon D-C, Lee C-S, Woo M-H, Lee ES, Jahng Y, et al. Cytotoxicity and DNA topoisomerase inhibitory activ